The EMPEROR-Preserved trial demonstrated that empagliflozin significantly reduces the composite risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF).
Empagliflozin showed consistent benefit across a broad range of ejection fractions, including patients with ejection fraction >50%.
The drug was well tolerated, with a safety profile consistent with prior studies in heart failure.
This trial represents the first large-scale randomized evidence for effective pharmacotherapy in HFpEF, addressing a major unmet clinical need.
